text:
Yes ! You heard that right. Very soon you would see the hot and happening Boyapati Sreenu working with none other then the stylish star Allu Arjun. According to our special sources, Allu Arjun seems to have okayed Boyapati’s film which will soon shape up.
This film will soon go on floors once Bunny completes Rudramma Devi and Trivikram’s film. Boyapati is high on the success of Legend, and his name is time and again being associated with Chiranjeevi’s 150th film as a director. On the other hand, Allu Arjun is going great guns in his career, and is doing some interesting projects off late. If would be really interesting to see how Boyapti presents this stylish star in his typical angry young man’s role.
- Bellamokonda Sreenivas gets trolled for his Twitter post
- Creative director in search of his lead cast
- Manoj releases a statement regarding his honor killing video
- NTR spotted spending lonely time in Milan
- Despite mixed response, Sarkar’s Simtaangaran storms YouTube

domain: celebrity


Crazy Costumes & Fighter Entrances on the Halloween Edition of MMA Newsmakers
- Posted by konrad3 on Oct 31, 2013
- 384 views
http://www.fightnetwork.com - Fight Network's John Pollock, John Ramdeen & Robin Black present our Halloween edition of MMA Newsmakers looking at crazy costumes and insane fighter entrances.
For additional coverage of MMA, boxing and pro-wrestling check out http://fightnetwork.com/ or follow us on Twitter at
https://twitter.com/fightnet or find us on Facebook at


Panasonic T10 Dual SIM Android Smartphone Launched At Rs 3,690
Photo Credit :
Panasonic India has launched its new Love T10 smartphone priced at Rs 3690. The company has confirmed that Smartphone Panasonic LOVE T10 will be available to consumers in India from the last week of July, 2015 in White & Black colors.
The Panasonic LOVE T10 is the first offering of the LOVE series of smartphones dedicated to the youth segment with complete connectivity suite covering Dual SIM 3G HSPA, Bluetooth™ 4.0 A2DP, Wi-Fi Hotspot at an attractive price. LOVE T10 is 8.89cm (3.5) LCD Display & weighs only 100 grams.
The device is powered by 1GHz Dual Core processor and runs on Android™ 4.4.2(Kitkat) with 4GB internal memory support. The smart gadget sports 2MP camera & houses a battery capacity of 1400mAh. LOVE T10 supports 21 Indian regional languages for the diverse Indian consumers; the supported languages are Hindi, Gujarati, Punjabi, Malayalam, Tamil, Telugu, Kannada, Oriya, Bengali, Assamese, Marathi, Nepali, Bodo, Dogri, Konkani, Urdu, Maithili, Manipuri, Sanskrit, Sindhi & Santali.
Pankaj Rana, Business Head – Mobility Division, Panasonic India, said, “Smartphones today have overtaken personal computers and tablets to become the ultimate gateway for those who want to connect to the internet on-the-go. Due to a surge in mobile internet users outpacing the growth in the Indian market, we have an introduced this device which not only meets the affordability aspect but also supports vernacular languages for our consumers. Catering to the needs of masses as well as the classes, the LOVE T10 is a perfect device that offers a blend of technology and design making it a smart utility product.”
(BW Online Bureau)


text:
Honeywell International (NYSE: HON) unveiled a corporate makeover today that will tie its growth more strongly to aerospace technology and spin off other businesses as two publicly-traded companies by the end of 2018.
This move is the result of its comprehensive portfolio review, including its intention to separately spin off its Homes product portfolio and ADI global distribution business, as well as its Transportation Systems business, into two stand-alone, publicly-traded companies. The planned separation transactions are intended to be tax-free spins to Honeywell shareowners for U.S. federal income tax purposes and are expected to be completed by the end of 2018.
“Today’s announcement marks the culmination of a rigorous portfolio review involving a detailed assessment of every Honeywell business. As part of that review, we analyzed numerous criteria, including growth outlook, financial performance, market dynamics, potential for disruption, and, most importantly, assessment of fit as a Honeywell business,” said Honeywell President and CEO Darius Adamczyk. “The remaining Honeywell portfolio will consist of high-growth businesses in six attractive industrial end markets, each aligned to global mega trends including energy efficiency, infrastructure investment, urbanization, and safety. These businesses are best positioned to leverage Honeywell synergies from our technologies, financial and business models, and talent. Our simplified portfolio will offer multiple platforms for organic growth and margin expansion through further deployment of our world-class HOS Gold operating system and the Honeywell Sentience Platform. Honeywell will also have multiple levers for continuing to execute an aggressive capital deployment strategy, including a vigorous and disciplined M&A program.”
“The spun businesses will be better positioned to maximize shareowner value through focused strategic decision making and capital allocation tailored for their end markets,” Adamczyk said. “At Honeywell, we will continue our track record of execution, delivering growth, margin expansion, and aggressive capital allocation for our shareowners.”
- Plans to Spin Homes and the ADI Global Distribution Business, a ~$4.5B Business, and Transportation Systems, a ~$3.0B Business, into Two Independent, Publicly-Traded Companies by End of 2018
- Prospective Honeywell Portfolio Consists of High-Growth Businesses with Strong Operational and Technology Synergies, Focused on Six Key End Markets
- Independent Investment Decisions Will Position Spins to Thrive in Evolving End Markets
- Company Previews 3Q17 Results: Sales Up ~3% Reported, Up ~5% Organic; Earnings Per Share of ~$1.75
- New Leader Appointed for Home and Building Technologies Business Group; Smart Energy Business to Align with Performance Materials and Technologies
The new Homes and Global Distribution business will be a leader in the home heating, ventilation and air conditioning (HVAC) controls and security markets, and a leading global distributor of security and fire protection products. The business is expected to have annualized revenue of approximately $4.5 billion, a high-yield credit rating, approximately 13,000 employees, and financial responsibility for certain Honeywell legacy liabilities.
The new Transportation Systems business will be a global leader in turbocharger technologies with best-in-class engineering capabilities for a broad range of engine types across global automobile, truck and other vehicle markets. The business is expected to have annualized revenue of approximately $3 billion, a high-yield credit rating, approximately 6,500 employees and financial responsibility for Honeywell legacy automotive segment liabilities in an amount equal to our Bendix legacy asbestos liability.
The planned separations will not require a shareowner vote. Each spin-off will be subject to finalization of the contours of the spun-off business, assurance that the separation will be tax-free to Honeywell shareowners for U.S. federal income tax purposes, finalization of the capital structure of the three corporations, the effectiveness of appropriate filings with the U.S. Securities and Exchange Commission, final approval of the Honeywell Board of Directors, and other customary matters.
Company Previews Anticipated Strong Third-Quarter Results; Raises Low-End of Full-Year Guidance
Honeywell announced it anticipates strong third-quarter results. Sales are expected to be $10.1 billion, up 3% reported and up 5% organic, and earnings per share is expected to be $1.75, up 9% reported and up 16%* ex-divestitures, normalized for tax at 26%, driven by strong results at its Aerospace and Performance Materials and Technologies business groups. The Company also raised the low-end of its full-year 2017 earnings per share guidance by 5 cents to a new range of $7.05 – $7.10, excluding any pension mark-to-market adjustment. The Company will hold its quarterly earnings announcement on Friday, October 20, at 9:30 a.m. EDT.
* Earnings per share variance excludes 2016 divestitures and approximately $60 million of additional 3Q17 restructuring funding enabled by a lower than planned effective tax rate, normalized for tax at 26%.
New Leader Appointed for Home and Building Technologies Business Group
Effective immediately, Gary Michel will serve as president and CEO of Honeywell’s Home and Building Technologies (HBT) strategic business group. Michel will report to Adamczyk and serve as a company officer. Michel succeeds Terrence Hahn, who will move to a leadership role reporting to Adamczyk and will help prepare the Homes and ADI businesses for the spin.
Michel joins Honeywell from Ingersoll-Rand Company, where he has held a series of large leadership roles over the past 32 years. Most recently, he served as senior vice president and president, Residential HVAC and Supply, which he transformed to deliver substantial improvements in revenue and market share, operating income, commercialization processes, and technology platforms. Michel has also led Ingersoll-Rand’s Club Car; Road Development – Construction Technologies; and Utility Equipment – Construction Technologies businesses. Michel has held several other roles, including executive director, Corporate Development, and general manager, Aftermarket Division, for Europe, the Middle East and Africa. Michel earned his B.S. in mechanical engineering at Virginia Tech and his M.B.A. at the University of Phoenix.
“Gary has proven himself to be an innovative and energetic leader with a deep understanding of his customers and end markets and the ability to translate this knowledge into technology-differentiated offerings that bring value to customers,” Adamczyk said. “Gary is a welcome addition to our team and will help Honeywell continue to be a leader in connected technologies, building on our great positions in growing industries.”Source: honeywell.com

domain: finance


text:
With participation in afterschool programs on the rise, it is essential that childcare settings provide healthy opportunities for kids. By developing healthy behaviors early in their lives, kids are more likely carry on these habits into their futures.
Whether it’s engaging in outdoor activities, sports or indoor games, it’s vital that childcare providers incorporate physical activity into their policies and programs.
With coloring pages, posters, tip sheets and more, Shape Your Future offers a variety of ways to help afterschool and childcare programs instill healthy environments.
The importance of physical activity is monumental for students. Regular movement not only helps reduce childhood obesity, it helps students strengthen and stimulate their brains. A healthier mind means higher test scores, better classroom participation and fewer disciplinary problems.
Aside from improved physical fitness, active kids also gain valuable leadership and teamwork skills, as well as improved self-confidence and self-esteem.
Through in-school and afterschool programs, schools can create active school environments and help their students achieve academic success.
Here are just a few ways to get started:
- Daily recess
- Physical education classes
- Classroom-based physical activities
- Intramural athletic programs
- Afterschool activities
- Interscholastic sports programs

domain: sociology


285.00 SR 330.00 SR
VM410 is the over-ear headset equipped with premium audio and innovative structural design. The large 53mm graphene diaphragm drivers create a vibrant frequency and a focus on true sound pick-up with the 9.7mm microphone. The innovative metal junction allows for triple adjustments for optimal ergonomics and lightweight comfort. The Cougar VM410 will immerse you in every game session.
|Max. Input Power||100mw|
|Sensitivity at 1kHz||113+3dB|
|Impedance at 1kHz||32Ώ±15%|
|Mic Type||Noise Cancellation|
|Mic. Sensitivity at 1kHz||-113dB±3%|
|Mic. Frequency Response||20Hz-20kHz|
One headset to play them all—the Razer Barracuda X is a versatile, lightweight wireless gaming headset designed for seamless use across PC, PlayStation*, Nintendo Switch, and Android. TECH SPECS FREQUENCY RESPONSE...
Audio CUE Software Yes Surround Sound No Detachable Microphone Yes Rechargble Battery Yes Weight 0.352 Headset Frequency Response 20Hz - 20 kHz Headset Battery Life Up to 30 hours Headphone...
Audio CUE Software No Surround Sound No Detachable Microphone Yes Rechargeable Battery No Weight 0.25 Headset Frequency Response 20Hz - 20 kHz Headset Battery Life N/A Headphone Sensitivity 113dB (+/-3dB)...


text:
A novel polymer lithium - sulfur battery was developed by combining theory with experiment
- Dec 24, 2018 -
The researchers found that after more than 100 charging cycles, the capacity of the new li-sulfur battery was still double that of the traditional li-sulfur battery.
This figure shows the formation of complex ion clusters during the cycle of li-sulfur battery cells. These clusters consist of cationic polymer adhesives, battery electrolytes, and anionic sulfur active materials.
Lithium-sulphur batteries are a promising alternative to conventional lithium-ion batteries in electric cars, because they are cheaper, lighter and can store nearly twice as much energy for the same mass. However, over time, li-sulfur batteries become unstable and their electrodes deteriorate, limiting their widespread use.
Recently, a research team led by scientists at Lawrence Berkeley national laboratory of the us department of energy found that compared with traditional li-sulfur batteries, the capacity of the new li-sulfur battery modules doubles and the charging cycle at high current density exceeds 100 times, which is a key performance indicator used in electric vehicles (EV) and aviation. They designed a new polymer binder to actively regulate key ion transport processes in lithium-sulphur batteries and showed how it works at the molecular level.
Brett Helms, a scientist at Lawrence Berkeley laboratory's molecular foundry institute, said:New polymer is like a wall in the main body in the pore of carbon, sulphur load and the polymer sealing, due to the chemical reaction of sulfur in the battery, stop the negatively charged polymer sulfur compounds are free to go out, and then produced the next generation of electric cars when lithium sulfur batteries to store and release energy, chemical reaction to produce mobile sulfur molecules, disconnected and electrode, decomposition and eventually lead to reduce the capacity of the battery in order that the battery is more stable, the researchers have been trying to develop for the protection of the electrode coating, and the development of new polymer adhesive will battery components togetherThese traditional adhesive to control or reduce the expansion of the electrode and cracking, the new adhesive is further from the Lawrence Berkeley laboratory of the centre for the study of molecular foundry, the researchers designed a kind of polymer by selectively combined sulfur molecules, sulfur will keep in close to the position of the electrode, offset the tendency of the next step is to understand the migration in the process of charging and discharging, as well as the possibility of dynamic structure under different charging status changes, the guiding theory of casting facilities facilities project scientist David Prendergast and theory of TodPascal developed a hypothesis to simulate testing polymer behavior Prendergast said:We can now reliably and efficiently in the adhesive curing learning model, based on the dissolved from the sulfur product detailed simulation of quantum mechanics in Lawrence Berkeley laboratory of national energy research scientific computing center (NERSC) super computing resources on a large scale molecular dynamics simulation, confirmed that the affinity of the polymer is combined with mobile sulfur molecules, and also predicts the polymer can be used in battery charging condition of different sulfur material using Lawrence BerkeleyLaboratory of advanced light source and the argonne national laboratory in electrochemistry lab experiments confirmed the prediction research group to further study the performance of the new polymer adhesive preparation of lithium sulfur batteries through a series of experiments, they can analyze and quantify the polymer of the sulfur cathode how to influence the chemical reaction rate, which is to achieve these batteries with high current density and high power key through long-term circulation increase battery capacity nearly doubled, new type of polymer to improve the capacity of the lithium battery and powerThe U.S. department of energy's joint center for energy storage and research (JCESR) 's comprehensive understanding of the synthesis, theory and properties of the new polymer makes it a key component of the prototype lithium-sulfur battery

domain: chemistry


text: I get it now. I’m never going to be the one who makes you change. I’m never going to be the one who makes you want to settle down. That’s fine. We’re young so I can’t be mad at you for wanting to enjoy life to the fullest. As much as it hurts me that there’s no way of knowing if i’ll even speak to you again, I know I’ll be fine. I spent the greater part of our “relationship” holding you up to an impossible standard and then making excuses for you when you failed to meet my expectations. I never really stopped to think that you taught me more than anyone I have ever known. I want to be with you so badly. I want to sneak into your room and watch movies late at night and drink wine and feel your body heat against mine. I want to be mad at you but not able to resist you at the same time. I want to spend hours picking out the perfect outfit, even though regardless of how I look you tell me I’m gorgeous. I want to force myself to get out of the car when you drop me off in the morning after the perfect goodbye kiss. I spend so much time focusing on what I want. When I should be focusing on what I need. I need to let you go. I need to find someone who wants me and only me. I need to realize that you taught me how to be close to someone. You taught me the real meaning of intimacy. You taught me how to love. Unconditionally. Meaning that today I just want to put it out into the universe that I love you. I no longer care if you love me back. I care about you more than you will probably ever know but it doesn’t matter if you do or not. It feels so good to have the capacity to really love someone and I think that is the reason that you came into my life. I learned patience, empathy, responsibility… It took hearing from you that I should follow my dreams and now I really feel like I’ll be okay in life. I feel the most stable I have ever felt. Thank you so much. Thanks for taking the time to let me learn how to love someone the right way. I hope that you find a girl that opens your eyes the way you have mine. I hope you realize that your friends and family really love you and that you’re not alone. If that’s the reason you’re out there everyday searching for something more than I hope you find some peace in the realization that you don’t have to try. There are people out there, just like me, who just love you. Plain and simple. Unconditionally. If I get the chance and you walk back into my life, I won’t hesitate to thank you. For now I’ll just put my love out there for someone else to stumble upon. Enjoy your moments.

domain: literature


Dave Sidhu is currently on a roll. Although a few films old, the director has already proved his mettle with some of his stunning creativity in all of his films. Sidhu is all set to turn a year older on November 2 and this is how the director will be celebrating his special day.
Dave Sidhu revealed his birthday plans in a recent interview and said that it would be a quiet one at home, stating that he was more of a pyjama party person and would prefer to spend time with family and friends. However, he did point out that her wife might have something up her sleeve.
The source further added that He has been a volunteer of the Red Cross for many years and donates blood every year on his birthday.
Let’s take a look at Dave Sidhu’s life journey and see how he made it in the film industry. Born Jatinder Singh and his wife Surjeet Kaur and brought up in Barnala, Punjab. He completed a diploma in filmmaking from Australian Film Institute (AFI).
Dave Sidhu started his career as a casting director with Pareshaan Parinda after which he did Kuriyan Jawan Baapu Preshaan. Along with directing and producing several music videos. Sidhu ventured into film direction in 2020 with The Oneness (a short documentary film on Indo-Australian people).
On the work front, he has his pockets full with films like JPS Canada and PCA Australia’s documentary short ‘Qaida-E-Noor’, Freshly Ground Entertainment’s ‘Yaariyan Dildariyaan’, Tracktouch Production’s ‘Untitled’ starring faces from bollywood and a docu-drama web series ‘The Maharaja’.


text:
These items are not for sale and the descriptions, images and prices are for reference purposes only.
English hallmarked sterling silver George V teapot having a rectangular body, with a band of hand-engraved shell & scroll detail, monogrammed 'Bma', a rectangular handle, finial & scroll spout, with a flat-hinged domed lid, standing on four
A quality William IV silver spinster's tea pot, elegant baluster form, heavily scroll floral and leaf embossed, the pedestal foot with everted acanthus leaves, sculpted floral hinge lid finial, ivory heat rings, crested. London 1836 by Joseph Angell I
Victorian sterling silver teapot, inscribed: 'Presented by His Royal Highness the Prince of Wales to James Cross on his marriage Sept. 1861', hallmarked London 1861, 675g approx., 26 cm spout to handle.
German silver 800 standard teapot having a dragon handle, goose spout, all over raised flower patterns, a relief panel of a courting couple, with a domed lid & four scrolled cherubic feet. Condition good to fair, some dents & tarnishing. Height 22.
An early Victorian sterling silver teapot, by John Samuel Hunt, London 1851, with early Victorian sterling silver stand by Charles Thomas fox & George fox, London 1847, of compressed form with floral finial, 13 cm high, 514 grams, stand 138 grams (2)
Russian silver teapot having a tapered neck & round bellied body with ribbed detail. St Petersburg, 1881, maker Ivan Vonifatiyevich Yevstigneyev. Condition: good. Minor wear to the base, slightly loose handle. Height 19.5 cm. Weight 769g
George IV sterling silver teapot circular shape, with flower head finial, gadrooned rim, acanthus topped handle, ribbed band to the body on 4 stylised scroll feet, engraved presentation inscription, London, 1824
English hallmarked sterling silver Victorian Bachelor teapot having a round body with hand-chased curved half fluting, with a band of hand-engraved gadrooned raised decoration, a dragon & fleur de lis cartouche, a pie crust edge cape border, wooden ins
English hallmarked sterling silver George V teapot having an oval body with hand-chased half fluting, a wooden insulated handle, a hinged domed lid with wooden finial, & all sitting on a collet foot. Birmingham, 1911, maker mark rubbed. Condition: good
A sterling silver teapot, 1900 Birmingham, with maker's mark for W J Rogers, the neoclassical boat shaped teapot with a gadrooned lower body and similar decoration to the lid and spout, with an ebonised bracket handle and lobed finial; hallmarked to th
A sterling silver teapot, 1912 Chester, with rubbed maker's mark for Nathan & Hayes, of neoclassical inspiration having a boat shaped body with fluted and cushion profile bands to the upper body, a small domed lid with an ebonised finial and a '
English hallmarked sterling silver Edward VII teapot having a domed hinged lid, & decorated with raised floral detail. Birmingham, 1902, maker Williams Birmingham Ltd. Condition fair, slightly loose hinge & handle, some tarnishing. Length 28.5 cm.
A fine Georgian sterling silver teapot, 1804 London, with maker's mark for Paul Storr, of elegant and restrained neoclassical design, the low oval teapot with a waisted collar and recessed lid with a bursting fruit finial, decorated with guilloche, mesh an
A fine sterling silver Adams style pedestal teapot, 1911 Sheffield, with maker's marks for James Dixon & Sons, elegant and restrained, the tapering ovoid body with a convex collar and domed lid with pine cone finial, a timber 'C' scroll handle with an acan
A large Victorian sterling silver pedestal teapot, 1864 London, with maker's marks for probably William hunter, the large ovoid teapot of rococo revival styling with a domed lid and lobed finial, an applied shell and scroll rim, embossed and chased to
A George III sterling silver teapot, 1806 London, with maker's marks for Alexander field, of typical compressed and waisted boat shape form with a pagoda dome lid, decorated with various bright cut and prick worked borders, having key fret and engraved
English hallmarked sterling silver George IV teapot having a baluster body with hand-chased half fluting, two heart shaped cartouches with one monogrammed 'Gj', an applied gadroon & shell border, reeded insulated handle with acanthus thumb rest
We do not automatically renew subscriptions, however you will be contacted prior to the expiry date and you may choose to renew if you wish.
We offer library subscriptions at competitive rates for both in-library access via IP address and off-library access through EZproxy software or similar. One subscription covers all libraries in your group.

domain: artistic


A DIAMOND duo celebrated their 60th wedding anniversary - and revealed their secret to a long and happy married life: “Love, trust, and give and take”.
Arthur and Betty Goodman, both 81, celebrated their big day with friends and family at Teesside Golf Club.
The pair were married on August 23, 1952, at St James’ Church, in Stockton. The service was followed by a reception at the church hall, on Norton Road, where alcohol was strictly banned.
And they then embarked on a honeymoon to the Isle of Man - which cost a total of £22 each.
The happy couple had met as teenagers at a dance at The Carlton Dance Hall, in Norton, four years earlier.
“Arthur was there and I was with my friends,” said Betty, a retired shop worker. “They asked me to get up and dance and that was it.
“We were 17 when we met. We courted for four years and got married when we were 21.”
Arthur and Betty both grew up in Stockton but moved to Thornaby together in the 1950s.
Arthur worked as a bricklayer, and also completed two years national service, while Betty worked in local shops.
Parents of Stephen, 57, Elaine, 53, and Tracey, 50, they also have seven grandchildren - Nicola, 31, Laura, 28, Sophie, 21, Cara, 17, Evie, 12, and twins Lily and Jack, nine.
“I must admit we have had a nice life!” said Betty.


text:
Update on Anti-NYRI Battle
By Sen. David J. Valesky
The battle against the New York Regional Interconnect power line proposal continues on several fronts. Representatives at the federal, state and local levels are all working together to combat this project and to collectively oppose the federal government’s National Interest Electric Transmission Corridor (NIETC) draft designation for our area – a designation that could ease this project's approval.
As many readers are aware, Congressman Mike Arcuri (D-Utica) held two public gatherings in the past month and also recently testified before the U.S. Department of Energy’s public comment hearing on the issue of NIETC draft designation held in Rochester.
The state legislature was in session during this hearing, so I and other State Senators were unable to attend. But that did not stop us from submitting testimony. Together with Sen. Joseph Griffo (R-Rome) and several other colleagues, I submitted testimony to the Energy Department’s hearing opposing this draft designation and reiterating New York State’s right to pursue our own energy solutions without federal interference.
Prior to the federal hearing in Rochester, Sen. Griffo and I also made known our vehement opposition to the location of the public comment hearing. Simply put, we said that it was not right for the federal energy department to hold the public comment hearing 130 miles or more away from the public most directly impacted by the lone proposed project in the Northeast’s draft corridor area.
Also last week, the State Senate passed a resolution formally registering our opposition to the NIETC designation for a large portion New York State, and several other states. In the resolution, we also sought the support of these neighboring states in opposing the federal energy department interference in state energy policies.
As is clear, the fight against the NYRI proposal continues and will until this project is defeated. As always, I will be working with my colleagues on both sides of the aisle and on all levels of government, to defeat this power line. And I know the citizens groups organized against the proposal will do the same.

domain: politics


Barbie Almalbis celebrated 25 years in the industry and held an anniversary concert, with other artists as guests. Watch her full interview below, as she shares the highlights of her career on Tag 91.1.
She also recently released a single, "Piraso" - in collaboration with other artists, namely Mark Escueta (Riverymaya), Pochoy Labog (Dicta License), and Jarlo Base (singer/producer). 'Piraso' is a soulful track that unfolds with both tenderness and power.
For more music updates tune in to Tag 91.1.


Dr Oz: What Would You Do in an Uncomfortable Health Situation?
Dr. Oz decided to turn the cameras for an investigation into human nature. He wanted to see what people would do if they witnessed an uncomfortable health situation. Would you speak up and get involved or would you stay quiet and mind your own business? Dr. Oz says he was surprised to see how people reacted to certain situations when they thought nobody was watching.
Dr Oz: Waitress Insults Overweight Diner
Dr. Oz and his team took over a New York City diner and set up a scenario where a waitress offers unsolicited advice to an overweight customer who she thinks is ordering way too much unhealthy food. He also asked life coach Gabrielle Bernstein to be his eyes and ears as she looked on via hidden camera to see how other diners reacted to the waitress’s comments.


text:
OnePlus’ latest set of wireless earbuds is also the first to get its Nord branding, which the company uses for its cheaper products. The new Nord Buds are being announced today alongside teases for two new entries to OnePlus’ European Nord smartphone lineup: the Nord 2T 5G and the Nord CE 2 Lite 5G.
The Nord Buds actually have a fair amount going for them, even at $39.99. They don’t have active noise cancellation, and they only have two mics in each stem rather than three like the $99 Buds Z2. But they’re rated for the same seven hours of battery life (38 hours combined with the case), and promise the same low latency — especially when connected to a OnePlus phone with ProGaming mode on — and fast charging.
The Nord Buds also have 12.4mm drivers, Dolby Atmos support, “AI powered noise reduction algorithms” for phone calls, and a new design OnePlus says makes them even more comfortable for long listening sessions.
One way to think about it is the Nord Buds are the AirPods to the Buds Z2’s AirPods Pro. (Which I guess makes the $150 Buds Pro, which also add wireless charging and adaptive noise cancellation, the AirPods Max? This isn’t a perfect analogy.) The Nord Buds are meant to be the entry-level model in the lineup, though now that you can buy the last-generation Buds Z for the same price, the OnePlus catalog is starting to get a bit confusing.
And that’s just when it comes to wireless earbuds. OnePlus is also pre-announcing two new Nord smartphones for the European market today: the OnePlus Nord 2T 5G and the OnePlus Nord CE 2 Lite 5G. The Nord 2T is meant as a spec bump to last year’s Nord 2 and now features 80W fast charging, up from 65W last time. Meanwhile, the Nord CE 2 Lite is being pitched as a step-down model compared to the Nord CE 2, which was itself a step down from the Nord 2. (It’s okay to be confused.) OnePlus plans to properly launch both phones on May 19th, when we can expect pricing and release date information.
While OnePlus is still mostly known as a phone brand, its headphones tend to outshine their price. The Verge’s Chris Welch found the Buds Pro both comfortable to wear and impressive in their audio quality, and they’ve earned a spot on our list of the best wireless earbuds you can buy.
In general, we’re seeing a huge drop in the cost of a pair of half-decent wireless earbuds. While it seems unlikely the Nord Buds will best some of the higher-end models on the market, and even competing with slightly more expensive models like the Jabra Elite 3 is a big ask, it wasn’t that long ago that $100 was the bare minimum for a decent pair. It’s encouraging to see that price dip all the way down to $40.

domain: news


text:
"The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.
Multiple myeloma is a form of blood cancer that p"...
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation.
Endogenous G-CSF is a lineage specific colony-stimulating factor which is produced by monocytes‚ fibroblasts, and endothelial cells. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation‚2‚3 differentiation,2‚4 and selected end-cell functional activation (including enhanced phagocytic ability‚5 priming of the cellular metabolism associated with respiratory burst‚6 antibody dependent killing,7 and the increased expression of some functions associated with cell surface antigens8). G-CSF is not species specific and has been shown to have minimal direct in vivo or in vitro effects on the production of hematopoietic cell types other than the neutrophil lineage.
Filgrastim was administered to monkeys‚ dogs‚ hamsters‚ rats‚ and mice as part of a preclinical toxicology program which included single-dose acute‚ repeated-dose subacute‚ subchronic‚ and chronic studies. Single-dose administration of Filgrastim by the oral‚ intravenous (IV)‚ subcutaneous (SC)‚ or intraperitoneal (IP) routes resulted in no significant toxicity in mice‚ rats‚ hamsters‚ or monkeys. Although no deaths were observed in mice‚ rats‚ or monkeys at dose levels up to 3450 mcg/kg or in hamsters using single doses up to approximately 860 mcg/kg‚ deaths were observed in a subchronic (13- week) study in monkeys. In this study‚ evidence of neurological symptoms was seen in monkeys treated with doses of Filgrastim greater than 1150 mcg/kg/day for up to 18 days. Deaths were seen in 5 of the 8 treated animals and were associated with 15- to 28-fold increases in peripheral leukocyte counts‚ and neutrophil-infiltrated hemorrhagic foci were seen in both the cerebrum and cerebellum. In contrast‚ no monkeys died following 13 weeks of daily IV administration of Filgrastim at a dose level of 115 mcg/kg. In an ensuing 52-week study‚ one 115 mcg/kg dosed female monkey died after 18 weeks of daily IV administration of Filgrastim. Death was attributed to cardiopulmonary insufficiency.
In subacute‚ repeated-dose studies‚ changes observed were attributable to the expected pharmacological actions of Filgrastim (ie‚ dose-dependent increases in white cell counts‚ increased circulating segmented neutrophils‚ and increased myeloid: erythroid ratio in bone marrow). In all species‚ histopathologic examination of the liver and spleen revealed evidence of ongoing extramedullary granulopoiesis; increased spleen weights were seen in all species and appeared to be dose-related. A dose-dependent increase in serum alkaline phosphatase was observed in rats‚ and may reflect increased activity of osteoblasts and osteoclasts. Changes in serum chemistry values were reversible following discontinuation of treatment.
In rats treated at doses of 1150 mcg/kg/day for 4 weeks (5 of 32 animals) and for 13 weeks at doses of 100 mcg/kg/day (4 of 32 animals) and 500 mcg/kg/day (6 of 32 animals)‚ articular swelling of the hind legs was observed. Some degree of hind leg dysfunction was also observed; however‚ symptoms reversed following cessation of dosing. In rats‚ osteoclasis and osteoanagenesis were found in the femur‚ humerus‚ coccyx‚ and hind legs (where they were accompanied by synovitis) after IV treatment for 4 weeks (115 to 1150 mcg/kg/day)‚ and in the sternum after IV treatment for 13 weeks (115 to 575 mcg/kg/day). These effects reversed to normal within 4 to 5 weeks following cessation of treatment.
In the 52-week chronic‚ repeated-dose studies performed in rats (IP injection up to 57.5 mcg/kg/day)‚ and cynomolgus monkeys (IV injection of up to 115 mcg/kg/day)‚ changes observed were similar to those noted in the subacute studies. Expected pharmacological actions of Filgrastim included dose-dependent increases in white cell
counts‚ increased circulating segmented neutrophils and alkaline phosphatase levels‚ and increased myeloid:erythroid ratios in the bone marrow. Decreases in platelet counts were also noted in primates. In no animals tested were hemorrhagic complications observed. Rats displayed dose-related swelling of the hind limb‚ accompanied by some degree of hind limb dysfunction; osteopathy was noted microscopically. Enlarged spleens (both species) and livers (monkeys)‚ reflective of ongoing extramedullary granulopoiesis‚ as well as myeloid hyperplasia of the bone marrow‚ were observed in a dose-dependent manner.
Pharmacologic Effects of NEUPOGEN®
In phase 1 studies involving 96 patients with various nonmyeloid malignancies‚ NEUPOGEN® administration resulted in a dose-dependent increase in circulating neutrophil counts over the dose range of 1 to 70 mcg/kg/day.9-11 This increase in neutrophil counts was observed whether NEUPOGEN® was administered IV (1 to 70 mcg/kg twice daily)‚9 SC (1 to 3 mcg/kg once daily)‚11 or by continuous SC infusion (3 to 11 mcg/kg/day).10 With discontinuation of NEUPOGEN® therapy‚ neutrophil counts returned to baseline‚ in most cases within 4 days. Isolated neutrophils displayed normal phagocytic (measured by zymosan-stimulated chemoluminescence) and chemotactic (measured by migration under agarose using N-formyl-methionyl-leucyl-phenylalanine [fMLP] as the chemotaxin) activity in vitro.
The absolute monocyte count was reported to increase in a dose-dependent manner in most patients receiving NEUPOGEN®; however‚ the percentage of monocytes in the differential count remained within the normal range. In all studies to date‚ absolute counts of both eosinophils and basophils did not change and were within the normal range following administration of NEUPOGEN®. Increases in lymphocyte counts following NEUPOGEN® administration have been reported in some normal subjects and cancer patients.
White blood cell (WBC) differentials obtained during clinical trials have demonstrated a shift towards earlier granulocyte progenitor cells (left shift)‚ including the appearance of promyelocytes and myeloblasts‚ usually during neutrophil recovery following the chemotherapy-induced nadir. In addition‚ Dohle bodies‚ increased granulocyte granulation‚ and hypersegmented neutrophils have been observed. Such changes were transient and were not associated with clinical sequelae, nor were they necessarily associated with infection.
Absorption and clearance of NEUPOGEN® follows first-order pharmacokinetic modeling without apparent concentration dependence. A positive linear correlation occurred between the parenteral dose and both the serum concentration and area under the concentration-time curves. Continuous IV infusion of 20 mcg/kg of NEUPOGEN® over 24 hours resulted in mean and median serum concentrations of approximately 48 and 56 ng/mL‚ respectively. Subcutaneous administration of 3.45 mcg/kg and 11.5 mcg/kg resulted in maximum serum concentrations of 4 and 49 ng/mL‚ respectively‚ within 2 to 8 hours. The volume of distribution averaged 150 mL/kg in both normal subjects and cancer patients. The elimination half-life‚ in both normal subjects and cancer patients‚ was approximately 3.5 hours. Clearance rates of NEUPOGEN® were approximately 0.5 to 0.7 mL/minute/kg. Single parenteral doses or daily IV doses‚ over a 14-day period‚ resulted in comparable half-lives. The half-lives were similar for IV administration (231 minutes‚ following doses of 34.5 mcg/kg) and for SC administration (210 minutes‚ following NEUPOGEN® doses of 3.45 mcg/kg). Continuous 24-hour IV infusions of 20 mcg/kg over an 11- to 20-day period produced steady-state serum concentrations of NEUPOGEN® with no evidence of drug accumulation over the time period investigated. Pharmacokinetic data in geriatric patients ( ≥ 65 years) are not available.
Cancer Patients Receiving Myelosuppressive Chemotherapy
NEUPOGEN® has been shown to be safe and effective in accelerating the recovery of neutrophil counts following a variety of chemotherapy regimens. In a phase 3 clinical trial in small cell lung cancer‚ patients received SC administration of NEUPOGEN® (4 to 8 mcg/kg/day‚ days 4 to 17) or placebo. In this study‚ the benefits of NEUPOGEN® therapy were shown to be prevention of infection as manifested by febrile neutropenia‚ decreased hospitalization‚ and decreased IV antibiotic usage. No difference in survival or disease progression was demonstrated.
In the phase 3‚ randomized‚ double-blind‚ placebo-controlled trial conducted in patients with small cell lung cancer‚ patients were randomized to receive NEUPOGEN® (n = 99) or placebo (n = 111) starting on day 4‚ after receiving standard dose chemotherapy with cyclophosphamide‚ doxorubicin‚ and etoposide. A total of 210 patients were evaluated for efficacy and 207 evaluated for safety. Treatment with NEUPOGEN® resulted in a clinically and statistically significant reduction in the incidence of infection‚ as manifested by febrile neutropenia; the incidence of at least one infection over all cycles of chemotherapy was 76% (84/111) for placebo-treated patients‚ versus 40% (40/99) for NEUPOGEN®-treated patients (p < 0.001). The following secondary analyses were also performed. The requirements for in-patient hospitalization and antibiotic use were also significantly decreased during the first cycle of chemotherapy; incidence of hospitalization was 69% (77/111) for placebo-treated patients in cycle 1‚ versus 52% (51/99) for NEUPOGEN®-treated patients (p = 0.032). The incidence of IV antibiotic usage was 60% (67/111) for placebo-treated patients in cycle 1‚ versus 38% (38/99) for NEUPOGEN®-treated patients (p = 0.003). The incidence‚ severity‚ and duration of severe neutropenia (absolute neutrophil count [ANC] < 500/mm³) following chemotherapy were all significantly reduced. The incidence of severe neutropenia in cycle 1 was 84% (83/99) for patients receiving NEUPOGEN® versus 96% (106/110) for patients receiving placebo (p = 0.004). Over all cycles‚ patients randomized to NEUPOGEN® had a 57% (286/500 cycles) rate of severe neutropenia versus 77% (416/543 cycles) for patients randomized to placebo. The median duration of severe neutropenia in cycle 1 was reduced from 6 days (range 0 to 10 days) for patients receiving placebo to 2 days (range 0 to 9 days) for patients receiving NEUPOGEN® (p < 0.001). The mean duration of neutropenia in cycle 1 was 5.64 ±2.27 days for patients receiving placebo versus 2.44 ±1.90 days for patients receiving NEUPOGEN®. Over all cycles‚ the median duration of neutropenia was 3 days for patients randomized to placebo versus 1 day for patients randomized to NEUPOGEN®. The median severity of neutropenia (as measured by ANC nadir) was 72/mm³ (range 0/mm³ to 7912/mm³) in cycle 1 for patients receiving NEUPOGEN® versus 38/mm³ (range 0/mm³ to 9520/mm³) for patients receiving placebo (p = 0.012). The mean severity of neutropenia in cycle 1 was 496/mm³ ±1382/mm³ for patients receiving NEUPOGEN® versus 204/mm³ ±953/mm³ for patients receiving placebo. Over all cycles‚ the ANC nadir for patients randomized to NEUPOGEN® was 403/mm³‚ versus 161/mm³ for patients randomized to placebo. Administration of NEUPOGEN® resulted in an earlier ANC nadir following chemotherapy than was experienced by patients receiving placebo (day 10 vs day 12). NEUPOGEN® was well tolerated when given SC daily at doses of 4 to 8 mcg/kg for up to 14 consecutive days following each cycle of chemotherapy (see ADVERSE REACTIONS).
Several other phase ½ studies‚ which did not directly measure the incidence of infection‚ but which did measure increases in neutrophils‚ support the efficacy of NEUPOGEN®. The regimens are presented to provide some background on the clinical experience with NEUPOGEN®. No claim regarding the safety or efficacy of the chemotherapy regimens is made. The effects of NEUPOGEN® on tumor growth or on the anti-tumor activity of the chemotherapy were not assessed. The doses of NEUPOGEN® used in these studies are considerably greater than those found to be effective in the phase 3 study described above. Such phase ½ studies are summarized in the following table.
|Type of Malignancy||Regimen||Chemotherapy Dose||No. Pts.||Trial Phase||NEUPOGEN® Daily Dosagea|
|Small Cell Lung Cancer||Cyclophosphamide Doxorubicin Etoposide||1 g/m²/day
50 mg/m²/day 120 mg/m²/day x 3
q 21 days
|210||3||4 — 8 mcg/kg SC
days 4 — 17
|Small Cell Lung Cancer11||Ifosfamide Doxorubicin Etoposide
120 mg/m²/day x 3 8 g/m²/day
q 21 days
|12||1 /2||5.75 - 46 mcg/kg IV
days 4 — 17
|Urothelial Cancer12||Methotrexate Vinblastine Doxorubicin Cisplatin||30 mg/m²/day x 2
3 mg/m²/day x 2
70 mg/m²/day q 28 days
|40||½||3.45 — 69 mcg/kg IV
days 4 — 11
|Various Nonmyeloid Malignancies13||Cyclophosphamide Etoposide
|2.5 g/m²/day x 2
500 mg/m²/day x 3
50 mg/m²/day x 3
q 28 days
|18||½||23 — 69 mcg/kgb IV
days 8 — 28
|Breast/Ovarian Cancer14||Doxorubicinc||75 mg/m²
q 14 days
|21||2||11.5 mcg/kg IV
days 2 — 9 5.75 mcg/kg IV
days 10 — 12
|Neuroblastoma||Cyclophosphamide Doxorubicin Cisplatin||150 mg/m² x 7
q 28 days (cycles 1,3,5)
|12||2||5.45 — 17.25 mcg/kg SC
days 6 — 19
|a NEUPOGEN® doses were those that accelerated
neutrophil production. Doses which provided no additional acceleration beyond
that achieved at the next lower dose are not reported.
b Lowest dose(s) tested in the study.
c Patients received doxorubicin at either 75‚ 100‚ 125‚ or 150 mg/m².
d Cycles 2‚6 = cyclophosphamide 150 mg/m² x 7 and etoposide 280 mg/m² x 3. Cycle 4 = cisplatin 90 mg/m² x 1 and etoposide 280 mg/m² x 3.
Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy
In a randomized, double-blind‚ placebo-controlled‚ multi-center‚ phase 3 clinical trial‚ 521 patients (median age 54‚ range 16 to 89 years) were treated for de novo acute myeloid leukemia (AML). Following a standard induction chemotherapy regimen comprising daunorubicin, cytosine arabinoside, and etoposide15 (DAV 3+7+5), patients received either NEUPOGEN® at 5 mcg/kg/day or placebo, SC, from 24 hours after the last dose of chemotherapy until neutrophil recovery (ANC 1000/mm³ for 3 consecutive days or 10,000/mm³ for 1 day) or for a maximum of 35 days.
Treatment with NEUPOGEN® significantly reduced the median time to ANC recovery and the median duration of fever, antibiotic use, and hospitalization following induction chemotherapy. In the NEUPOGEN®-treated group‚ the median time from initiation of chemotherapy to ANC recovery (ANC ≥ 500/mm³) was 20 days (vs 25 days in the control group, p = 0.0001), the median duration of fever was reduced by 1.5 days (p = 0.009), and there were statistically significant reductions in the durations of IV antibiotic use and hospitalization. During consolidation therapy (DAV 2+5+5), patients treated with NEUPOGEN® also experienced significant reductions in the incidence of severe neutropenia, time to neutrophil recovery, the incidence and duration of fever, and the durations of IV antibiotic use and hospitalization. Patients treated with a further course of standard (DAV 2+5+5) or high-dose cytosine arabinoside consolidation also experienced significant reductions in the duration of neutropenia.
There were no statistically significant differences between NEUPOGEN® and placebo groups in complete remission rate (69% NEUPOGEN® vs 68% placebo, p = 0.77), disease-free survival (median 342 days NEUPOGEN® [n = 178], 322 days placebo [n = 177], p = 0.99), time to progression of all randomized patients (median 165 days NEUPOGEN®, 186 days placebo, p = 0.87), or overall survival (median 380 days NEUPOGEN®, 425 days placebo, p = 0.83).
Cancer Patients Receiving Bone Marrow Transplant
In two separate randomized‚ controlled trials‚ patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with myeloablative chemotherapy and autologous bone marrow transplantation (ABMT). In one study (n = 54)‚ NEUPOGEN® was administered at doses of 10 or 30 mcg/kg/day; a third treatment group in this study received no NEUPOGEN®. A statistically significant reduction in the median number of days of severe neutropenia (ANC < 500/mm³) occurred in the NEUPOGEN®-treated group versus the control group (23 days in the control group‚ 11 days in the 10 mcg/kg/day group‚ and 14 days in the 30 mcg/kg/day group [11 days in the combined treatment groups‚ p = 0.004]). In the second study (n = 44‚ 43 patients evaluable)‚ NEUPOGEN® was administered at doses of 10 or 20 mcg/kg/day; a third treatment group in this study received no NEUPOGEN®. A statistically significant reduction in the median number of days of severe neutropenia occurred in the NEUPOGEN®-treated group versus the control group (21.5 days in the control group and 10 days in both treatment groups‚ p < 0.001). The number of days of febrile neutropenia was also reduced significantly in this study (13.5 days in the control group‚ 5 days in the 10 mcg/kg/day group‚ and 5.5 days in the 20 mcg/kg/day group [5 days in the combined treatment groups‚ p < 0.0001]). Reductions in the number of days of hospitalization and antibiotic use were also seen‚ although these reductions were not statistically significant. There were no effects on red blood cell or platelet levels.
In a randomized‚ placebo-controlled trial‚ 70 patients with myeloid and nonmyeloid malignancies were treated with myeloablative therapy and allogeneic bone marrow transplant followed by 300 mcg/m²/day of a Filgrastim product. A statistically significant reduction in the median number of days of severe neutropenia occurred in the treated group versus the control group (19 days in the control group and 15 days in the treatment group‚ p < 0.001) and time to recovery of ANC to ≥ 500/mm³ (21 days in the control group and 16 days in the treatment group‚ p < 0.001).
In three nonrandomized studies (n = 119)‚ patients received ABMT and treatment with NEUPOGEN®. One study (n = 45) involved patients with breast cancer and malignant melanoma. A second study (n = 39) involved patients with HD. The third study (n = 35) involved patients with NHL‚ acute lymphoblastic leukemia (ALL)‚ and germ cell tumor. In these studies‚ the recovery of the ANC to ≥ 500/mm³ ranged from a median of 11.5 to 13 days.
While these studies were not designed to compare survival‚ this information was collected and evaluated. The overall survival and disease progression of patients receiving NEUPOGEN® in these studies were similar to those observed in the respective control groups and to historical data.
Peripheral Blood Progenitor Cell Collection and Therapy in Cancer Patients
All patients in the Amgen-sponsored trials received a similar mobilization/collection regimen: NEUPOGEN® was administered for 6 to 7 days‚ with an apheresis procedure on days 5‚ 6, and 7 (except for a limited number of patients receiving apheresis on days 4‚ 6, and 8). In a non-Amgen-sponsored study‚ patients underwent mobilization to a target number of mononuclear cells (MNC)‚ with apheresis starting on day 5. There are no data on the mobilization of peripheral blood progenitor cells (PBPC) after days 4 to 5 that are not confounded by leukapheresis.
Mobilization of PBPC was studied in 50 heavily pretreated patients (median number of prior cycles = 9.5) with NHL‚ HD, or ALL (Amgen study 1). CFU-GM was used as the marker for engraftable PBPC. The median CFU-GM level on each day of mobilization was determined from the data available (CFU-GM assays were not obtained on all patients on each day of mobilization). These data are presented below.
The data from Amgen study 1 were supported by data from Amgen study 2 in which 22 pretreated breast cancer patients (median number of prior cycles = 3) were studied. Both the CFU-GM and CD34+ cells reached a maximum on day 5 at > 10-fold over baseline and then remained elevated with leukapheresis.
Progenitor Cell Levels in Peripheral Blood by
|Overall Study 1
CD34* (x 104/mL)
|No. Samples|| Median
(25% - 75%)
(25% - 75%)
(25% - 75%)
(13 - 62)
(15 - 151)
(0.02 - 0.66)
|Day 2||7||2 61 2-
(39 - 364)
(158 - 864)
(108 - 1819)
(0.58 - 3.93)
(391 - 1608)
(72 - 1677)
(1.08 - 6.11)
(199 - 1397)
(70 - 3486)
(1.09 - 4.40)
(111 - 938)
(118 - 2009)
(0.78 - 4.22)
(94 - 815)
(10 - 746)
(0.38 - 4.31)
|n/a = not available|
In three studies of patients with prior exposure to chemotherapy‚ the median CFU-GM yield in the leukapheresis product ranged from 20.9 to 32.7 x 104/kg body weight (n = 105). In two of these studies where CD34+ yields in the leukapheresis product were also determined‚ the median CD34+ yields were 3.11 and 2.80 x 106/kg, respectively (n = 56). In an additional study of 18 chemotherapy-naive patients‚ the median CFU-GM yield was 123.4 x 104/kg.
Engraftment following NEUPOGEN®-mobilized PBPC is summarized for 101 patients in the following table. In all studies, a Cox regression model showed that the total number of CFU-GM and/or CD34+ cells collected was a significant predictor of time to platelet recovery.
In a randomized, unblinded study of patients with HD or NHL undergoing myeloablative chemotherapy (Amgen study 3)‚ 27 patients received NEUPOGEN®-mobilized PBPC followed by NEUPOGEN® and 31 patients received ABMT followed by NEUPOGEN®. Patients randomized to the NEUPOGEN®-mobilized PBPC group compared to the ABMT group had significantly fewer days of platelet transfusions (median 6 vs 10 days)‚ a significantly shorter time to a sustained platelet count > 20‚000/mm³ (median 16 vs 23 days)‚ a significantly shorter time to recovery of a sustained ANC ≥ 500/mm³ (median 11 vs 14 days)‚ significantly fewer days of red blood cell transfusions (median 2 vs 3 days) and a significantly shorter duration of posttransplant hospitalization.
|Amgen-sponsored Study 1
N = 13
|Amgen-sponsored Study 2
N = 22
|Amgen-sponsored Study 3
N = 27
N = 39
|Median PBPC/kg Collected||MNC||9.5 x 108||9.5 x 108||8.1 x 108||10.3 x 108|
|CD34+||n/a||3.1 x 106||2.8 x 106||6.2 x 106|
|CFU-GM||63.9 x 104||25.3 x 104||32.6 x 104||n/a|
|Days to ANC > 500/mm³||Median||9||10||11||10|
|Range||8 — 10||8 — 15||9 — 38||7 — 40|
|Days to Plt. > 20,000/mm³||Median||10||12.5||16||15.5|
|Range||7 — 16||10 — 30||8 — 52||7 — 63|
|n/a = not available|
Three of the 101 patients (3%) did not achieve the criteria for engraftment as defined by a platelet count ≥ 20‚000/mm³ by day 28. In clinical trials of NEUPOGEN® for the mobilization of PBPC‚ NEUPOGEN® was administered to patients at 5 to 24 mcg/kg/day after reinfusion of the collected cells until a sustainable ANC ( ≥ 500/mm³) was reached. The rate of engraftment of these cells in the absence of NEUPOGEN® posttransplantation has not been studied.
Patients With Severe Chronic Neutropenia
Severe chronic neutropenia (SCN) (idiopathic‚ cyclic‚ and congenital) is characterized by a selective decrease in the number of circulating neutrophils and an enhanced susceptibility to bacterial infections.
The daily administration of NEUPOGEN® has been shown to be safe and effective in causing a sustained increase in the neutrophil count and a decrease in infectious morbidity in children and adults with the clinical syndrome of SCN.16 In the phase 3 trial‚ summarized in the following table‚ daily treatment with NEUPOGEN® resulted in significant beneficial changes in the incidence and duration of infection‚ fever‚ antibiotic use‚ and oropharyngeal ulcers. In this trial‚ 120 patients with a median age of 12 years (range 1 to 76 years) were treated.
Overall Significant Changes in Clinical Endpoints Median
Incidencea (events) or Duration (days) per 28-day Period
|Control Patientsb||NEUPOGEN® -treated Patients||p-value|
|Incidence of Infection||0.50||0.20||< 0.001|
|Incidence of Fever||0.25||0.20||< 0.001|
|Duration of Fever||0.63||0.20||0.005|
|Incidence of Oropharyngeal Ulcers||0.26||0.00||< 0.001|
|Incidence of Antibiotic Use||0.49||0.20||< 0.001|
|a Incidence values were calculated for each
patient‚ and are defined as the total number of events experienced divided by
the number of 28-day periods of exposure (on-study). Median incidence values
were then reported for each patient group.
b Control patients were observed for a 4-month period.
The incidence for each of these 5 clinical parameters was lower in the NEUPOGEN® arm compared to the control arm for cohorts in each of the 3 major diagnostic categories. All 3 diagnostic groups showed favorable trends in favor of treatment. An analysis of variance showed no significant interaction between treatment and diagnosis‚ suggesting that efficacy did not differ substantially in the different diseases. Although NEUPOGEN® substantially reduced neutropenia in all patient groups‚ in patients with cyclic neutropenia‚ cycling persisted but the period of neutropenia was shortened to 1 day.
As a result of the lower incidence and duration of infections‚ there was also a lower number of episodes of hospitalization (28 hospitalizations in 62 patients in the treated group vs 44 hospitalizations in 60 patients in the control group over a 4-month period [p =0.0034]). Patients treated with NEUPOGEN® also reported a lower number of episodes of diarrhea‚ nausea‚ fatigue‚ and sore throat.
In the phase 3 trial‚ untreated patients had a median ANC of 210/mm³ (range 0 to 1550/mm³). NEUPOGEN® therapy was adjusted to maintain the median ANC between 1500 and 10‚000/mm³. Overall‚ the response to NEUPOGEN® was observed in 1 to 2 weeks. The median ANC after 5 months of NEUPOGEN® therapy for all patients was 7460/mm³ (range 30 to 30‚880/mm³). NEUPOGEN® dosing requirements were generally higher for patients with congenital neutropenia (2.3 to 40 mcg/kg/day) than for patients with idiopathic (0.6 to 11.5 mcg/kg/day) or cyclic (0.5 to 6 mcg/kg/day) neutropenia.
2. Welte K‚ Bonilla MA‚ Gillio AP‚ et al. Recombinant human G-CSF: Effects on hematopoiesis in normal and cyclophosphamide treated primates. J Exp Med. 1987;165:941-948.
3. Duhrsen U‚ Villeval JL‚ Boyd J‚ et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988;72:2074-2081.
4. Souza LM‚ Boone TC‚ Gabrilove J‚ et al. Recombinant human granulocyte colonystimulating factor: Effects on normal and leukemic myeloid cells. Science. 1986;232:61-65.
5. Weisbart RH‚ Kacena A‚ Schuh A‚ Golde DW. GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature. 1988;332:647-648.
6. Kitagawa S‚ Yuo A‚ Souza LM‚ Saito M‚ Miura Y‚ Takaku F. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by chemotactic peptide. Biochem Biophys Res Commun. 1987;1443:1146.
7. Glaspy JA‚ Baldwin GC‚ Robertson PA‚ et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Int Med. 1988;109:789-795.
8. Yuo A‚ Kitagawa S‚ Ohsaka A‚ et al. Recombinant human granulocyte colonystimulating factor as an activator of human granulocytes: Potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence. Blood. 1989;74:2144-2149.
9. Gabrilove JL‚ Jakubowski A‚ Fain K‚ et al. Phase I study of granulocyte colonystimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest. 1988;82:1454-1461.
10. Morstyn G‚ Souza L‚ Keech J‚ et al. Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. 1988;1:667-672.
11. Bronchud MH‚ Scarffe JH‚ Thatcher N‚ et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987;56:809-813.
12. Gabrilove JL‚ Jakubowski A‚ Scher H‚ et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med. 1988;318:1414-1422.
13. Neidhart J‚ Mangalik A‚ Kohler W‚ et al. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone-marrow transplantation. J Clin Oncol. 1989;7:1685-1691.
14. Bronchud MH‚ Howell A‚ Crowther D‚ et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer. 1989;60:121-128.
15. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of Filgrastim in remission induction and consolidation therapy for adults with de novo Acute Myeloid Leukemia. Blood. 1997;90:4710-4718.
16. Dale DC‚ Bonilla MA‚ Davis MW‚ et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (Filgrastim) for treatment of severe chronic neutropenia. Blood. 1993;81:2496-2502.
Last reviewed on RxList: 6/4/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Neupogen Information
Neupogen - User Reviews
Neupogen User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.

domain: medical


Independent Trading - MIdweight Fleece Jogger
8.5 oz./yd² (US) 14.2 oz./L yd (CA) 80/20 cotton/polyester blend fleece, ring spun cotton with 100% cotton face
Grey Heather: 52/48 cotton/polyester
Elastic waistband with shoestring drawcord
1x1 ribbing at ankle cuffs
Sewn fly detail
Back pocket & Jersey lined hand pockets
Tear away label
Ready to get started?
Submitting your information will put you in contact with someone from our team who can help.


text:
Massive Disneyland Attraction Database
Picture: Zombie's Lair on Marc Davis Island, a favorite attraction of Clara Cluck
Zombie's Lair on Marc Davis Island
May 15, 1975
Avg. queue length:
It's an island as depicted in the books of Abraham Lincoln -- only with less Marc Davis and more zombies! Fans of Marc Davis can crawl through zombie caves, enjoy cleverly themed zombie shipwrecks, and peek between the logs of a fort full of Fantasmic! equipment!
- Warning: during winter, this attraction will be hostile to tourists.
- After flapping this attraction, you will be physically unable to try something more exciting.
- WARNING! For your safety or comfort, you should be in good health or free from philosophical objections, clown makeup, or finger, attention-span, inner ear, skin, spinal, or leg problems, or other states that could lessen your enjoyment of this experience.
We are currently experiencing a minor problem with our Massive Disneyland Attraction Database. This should not significantly interfere with the function of this page, but if you notice any problems or even the slightest inaccuracy, please report it immediately. Thank you for your prayers.

domain: entertainment


Rick Astley is getting around lately. We recently saw him on a Canadian morning show for a live, in-person rickroll. Now he's singing his 1987 hit song, "Never Gonna Give You Up," with Choir! Choir! Choir! in Toronto.
Here's what Choir! Choir! Choir! wrote about it:
In March 2018, we made a video asking pop legend Rick Astley to come sing with us.
We just had a feeling it would be a perfect fit.
HE SHOWED UP two weeks later!!
And guess what?
We were right,
But it was even more incredible than we could have expected.
Rick looks and sounds better than ever.
He's back in a BIG way writing and performing all new material, Slaying it all over again.
He is the real deal, and always has been.
He also challenged another musician to come sing with us,
So look for that at the end of the video…
Rick is back on tour throughout the US right now, and his band is killer, So look out for him making his way to your town!
Now enjoy the best version of Never Gonna Give You Up EVER!


text:
The Mercedes-Benz Star Lounge serves as the first look at Iman’s designs for the collection, which launches in late September. IMAN Home marks Iman's first venture into the home decor industry adding to her current businesses, which include cosmetics, fragrance, apparel and accessories.
Iman has been featured on the covers of top fashion magazines around the world and has been a source of inspiration for designers such as Gianni Versace, Donna Karan, and Yves Saint-Laurent. On June 7, 2010, Iman was recognized for her contributions to the industry over the past thirty years by receiving the Fashion Icon Award from the Council of Fashion Designers of America.
"I am so excited to partner with Mercedes-Benz on this project," said Iman. "We have worked tirelessly in preparation for the launch of IMAN Home and to have this forum, at Mercedes-Benz Fashion Week, is a great way to unveil the collection."
Carlos Mota will also transform a an ordinary room inside Lincoln Center for Mercedes-Benz Fashion Week VIPs, by using cozy couches, chairs, daybeds, full bar and private sitting area. "This is an exciting project for me," said Mota. "It is great to be working with a team so attentive to detail and quality."
The Mercedes-Benz Star Lounge is available to designers, celebrities, VIPs, media and guests, by invitation or through an access card provided by Mercedes-Benz.

domain: design


An affiliate of Brazilian builder Davila Custom Homes and South American partners paid $1.145 million last week for 8.88 lakefront acres in the tourism corridor, with plans ahead for up to 80 high-end condominium apartments, a Brazilian architect soon to be chosen and a Miami-based brokerage pegged for presales.
GrowthSpotter first reported on June 15 that Davila had the land under contract, which lies southwest of SeaWorld on Lake Willis at 11302 and 11314 Westwood Blvd. The deed was signed July 12, and recorded with Orange County on Tuesday.
"We're moving forward now with the project, it will be 70 to 80 units, and we'll now go into rezoning, and start working on construction documents for development there," developer T.J. Davila said Tuesday.
The developer will finance via equity raises from Davila and investment partners from South America, and will attempt to pre-sell units. Davila said he's in final negotiations with Chris Brooks Realty out of Miami to market the property, a Brazilian-American brokerage which opened a retail store location in Orlando in February.
On the architecture front, Davila said his group has focused on two Brazilian architecture firms it should choose from soon, though declined to name them. Davila Homes will serve as general contractor on the project.
The homes will feature a "very modern Miami and South American design," and be priced near $300,000 unfurnished, Davila said.
He declined to offer a projected investment cost through buildout for the development, but estimated $22 million to $25 million in gross revenue after sales complete.
A Planned Development rezoning will come first, which would go through three stages of Orange County approval before Davila could then file a Development Plan.
Construction height on the parcels will be limited by the Lake Willis Neighborhood Overlay District to 20 feet (one story) within 100 feet of the southern boundary of their two contiguous parcels. Two-story units could be built on a portion of the site, but not all.
They'll also have to hold one or more community meetings with area residents, file a new CAD (Conservation Area Determination), and reach a school impact agreement with Orange County Public Schools.
The property was sold by Orlando-based River Business Corp., formed by Brazilian real estate investors Jose and Marjacy Oliveira, who now live in Houston. The couple paid $903,700 for the two parcels in 2011.
The land lies in a burgeoning multi-family corridor where more than 1,000 apartments are currently in various phases of pre-construction and construction, between four other projects.


text:
In the quest for a healthy lifestyle, the magic often lies in the simplest choices. One such choice is incorporating a variety of magical dry fruits into your daily diet. Packed with nutrients and flavor, these dry fruits offer more than just a delightful snack – they contribute to your overall well-being.
Versatile Almonds for Heart Health
Almonds, a powerhouse of nutrition, offer a versatile addition to your daily diet. Rich in fiber, protein, and healthy fats, they not only promote heart health but also provide sustained energy throughout the day.
Walnuts: Brain Food with a Crunch
For those seeking brain-boosting benefits, walnuts are the answer. Loaded with omega-3 fatty acids, they support brain health and may even help reduce inflammation. Add them to salads for a delightful crunch or enjoy them as a standalone snack.
Sweet and Nutritious Energy Bombs
If you’re looking for a sweet and nutritious energy boost, dates are the perfect choice. High in natural sugars and fiber, they not only satisfy your sweet tooth but also promote digestive health.
Concentrated Goodness in Every Bite
Raisins, those humble dried grapes, pack a punch of energy. Besides being a concentrated source of natural sugars, they provide essential minerals like iron and potassium. Enjoy them as a convenient snack or add them to various dishes for a touch of sweetness.
Cashews: The Delicious Nutrient Boost
Cashews, with their rich taste, contribute significantly to bone health and immune function. Packed with vitamins and minerals, they are a delicious addition to both sweet and savory dishes, offering a delightful crunch.
Dried Apricots: Antioxidant-Rich Goodness
Dried apricots bring a burst of antioxidants and fiber to the table. Not only do they promote skin health, but they also aid in digestion. Enjoy them as a standalone snack or incorporate them into your favorite dishes.
Pistachios: Unique Flavor, Nutrient-Rich
Known for their unique flavor, pistachios are a treat for the taste buds. Beyond that, they are rich in protein, fiber, and healthy fats. Whether enjoyed on their own or added to dishes, they provide a delightful crunch and nutritional benefits.
Prunes: Digestive Health in Every Bite
For digestive benefits, prunes are your go-to dry fruit. High in fiber and sorbitol, they support regular bowel movements. Prunes also offer a natural sweetness, making them a guilt-free indulgence.
Figs: Tasty and Nutritious Addition
Figs, a delightful addition to cereals or yogurt, bring a wealth of vitamins and minerals to your diet. High in potassium and magnesium, they contribute to overall well-being. Enjoy the taste while reaping the nutritional benefits.
In conclusion, these nine magical dry fruits are not just snacks; they are nutritional powerhouses that can transform your daily diet. From promoting heart health to aiding digestion, each dry fruit brings its unique set of benefits. It’s time to let these magical delights redefine your approach to snacking and nutrition.
- How many almonds should I eat daily for maximum benefits?
- Consuming around 1-2 ounces (28-56 grams) of almonds daily is recommended for optimal health benefits.
- Can I include these dry fruits in a weight loss diet?
- Yes, in moderation. While they are nutrient-dense, portion control is crucial for a balanced diet.
- Are the natural sugars in dates suitable for diabetics?
- Dates contain natural sugars, so moderation is key for individuals managing diabetes. Consult a healthcare professional for personalized advice.
- Can I use these dry fruits in cooking and baking?
- Absolutely! These dry fruits add flavor and nutrition to both sweet and savory dishes. Experiment and enjoy.
- How can I ensure the freshness of these dry fruits?
- Store them in airtight containers in a cool, dark place to maintain their freshness. Check regularly for any signs of spoilage.

domain: food


text:
Now a true African platform
for investment promotion, the first forum in 2018 secured investment interest for 49 projects worth $38.7 billion.
From the necessity of a collaborative African platform
to curb extremism to the urge of furthering intra-African exchanges, all the speakers agreed that the "African family" at the UN and other international organizations should show more unity and cohesion when discussing on issues of vital interest for the African continent.
However, the recognition of Africa as a beacon of hope for African people living on the continent and in the diaspora to explore, relate and live using the conference as the African platform
for the foundation of this long-lasting relationship.
(2) In 2017, the African Platform
for Human Resources for Health pleaded for an enhanced role of nursing in its declaration, but surprisingly, there was no mention of other health professionals.
(Tap) -- The first African platform
of virtual education was put in place by virtue of an agreement concluded Friday in Hammamet by African virtual universities.
Today, the re-engaging of the Egypt market by a much stronger SHUAA Securities is expected to pave the way for further expansion by the group's other business lines on the North African platform
over the medium term.
He described the AU as 'a unique African platform
of solidarity which must be more effectively utilized to tackle the critical issues affecting the continent and its peoples'.
Abidjan: Africa Day was the springboard for the official launch of Africa NDC Hub, the African Platform
for Nationally Determined Contributions (NDCs).
The IDUAI is an outcome of advocacy of the African Platform
on Access to Information (APAI) and building on work of FOIAnet.
At a time when some investment banks have retrenched in Africa, we see a real chance to develop a pan- African platform
, strengthening ties and economic ventures between a number of different nations," Ahmed Badr, Chief Executive Officer, MENA, Renaissance Capital, said.
The win-win policy or mutual benefit principle guiding the cooperation framework between Japan and Africa should be practical so that Japan does not fall in the bracket of development partners, who use the African platform
for their own selfish interests and more so to exploit natural resources in Africa.
The investigation of MultiChoice, led by Kenya's newly minted Competition Authority, alleges that the South African platform
used its exclusive deals for premium content--including the lucrative rights to soccer broadcasts from the English Premier League--to prevent competitors from gaining a foothold in Kenya.


It's a ruling that's sparking a lot of debate.
"it's very disappointing that women's access to affordable health care is reduced," Family Planning Health Services Outreach Coordinator Frances Irwin said.
"I think it's the right decision in regard to the question of freedom of religion," Hope Pregnancy Resource Center Executive Director Jack Hoogendyk said. "I think it was a good decision by the Supreme Court."
The Hope Pregnancy Center is a faith-based organization. But Hoogendyk says he also supports the ruling from a Constitutional point of view.
"The Constitution clearly states the freedom of religion of its citizens, and I think that's really the core of this issue," Hoodendyk said.
But organizations such as Family Planning Health Services don't support the court's decision.
"With no co-pay, and no deductible with insurance coverage, and with the Supreme Court's ruling today, those who work for privately held corporations may now have to pay full price for their birth control," Irwin said.
The Supreme Court's ruling may be settled. And while some may be in favor, it's evident that the Court's decision is one that hasn't settled well for everyone.


text:
Today’s track Time To Go (Before The Rivalry) comes from Oxford quartet ArtClassSink, and is taken from their new alternative-shoegaze EP, ILLA. The EP was released on November 25th and was released across all the usual platforms, iTunes, Amazon, etc. Some of the band’s recent gigs include tour support for We Are Augustines, SKATERS, This Town Needs Guns, Superfood, and Temples. From the looks of their success in 2013, we look forward to seeing what ArtClassSink have to offer in the new year.
[soundcloud url=”https://api.soundcloud.com/tracks/116888292″ params=”color=00c6ff&auto_play=false&show_artwork=true” width=”100%” height=”166″ iframe=”true” /]
Alicia Atout |


text:
Paying taxes 2016 zambia zambia: and the zra to improve capacity and reduce tax compliance and administration costs for taxpayers and the zra alike in addition. Sufficient level of tax compliance on the part of taxpayers ideally any government would want one hundred percent compliance which would mean optimal tax collection. Ejournal of tax research volume 12, number 2 november 2014 ontents regulation of tax agents in australia factors influencing taxpayers' compliance with the tax system: an. The perception of tax practitioners relating to the influence of the tax administration act on taxpayers' tax compliance behaviour in south africa i declare that the above dissertation is my own work and that all the sources that i have used or quoted. Tax compliance dissertation - hire the specialists to do your essays for you find main tips as to how to receive the greatest term paper ever proposals and essays at most affordable prices.
Compliance requirements sometimes you are too scared to contact the ird because they may think that you have broken the law (m4) they are terrified of the ird or anything relating to compliance even with the local government and things like. Integrity and tax compliance by occupational groups oscar vela, essays on the economics of individual tax compliance, phd dissertation, 2008 business income reporting has a large scope for potential underreporting, because the irs cannot as easily match third-party transaction reports to business tax returns the way it can with, say. Compliance requirements relevant to the organisation (from assessment 1, part a) 2 specification of compliance management functions, accountabilities and responsibilities within the organisation.
Social norms and tax compliance among small business enterprises in uganda jennifer nabaweesi 2006/hd10/5978u bcom (muk) and acca a research dissertation report submitted to makerere university in partial fulfillment for. Tax morale : theory and empirical analysis of tax compliance torgler, benno tax morale : theory and empirical analysis of tax compliance 2003, doctoral thesis, university of basel, faculty of business and economics. The ibfd's knowledge centre regularly releases white papers on various international tax related topics as a technique to increase vat compliance by. Managing and improving tax compliance 5 central to these reforms has been the establishment of sound corporate governance practices, including the application of modern risk management approaches. Death tax - also known as estate tax - is a form of taxation that only occurs after one is deceased and one's assets have been calculated depending upon how one's assets are left prior to one's demise, the amount of death tax to be paid is determined as a percentage on an incremental scale.
With the tax requirements, and (ii) to establish the relationship between income tax proficiencies and income tax compliance among smes in mbale district in uganda and to draw implications for developing countries. Tax compliance is a complex behavioral issue and investigation requires the use of a variety of methods and data sources as each instrument has strength and weaknesses since. South african small business' taxation registration tax compliance risk management system is to ensure registration for the relevant taxes payable. Tax compliance is a major problem for many tax authorities and is not an easy task to persuade tax payers to comply with (james & alley 2002) alm and maritnez-vasques. Tax compliance in zanzibar by shuweikha skhalfan a dissertation submitted in partial fulfillment of the requirements of the degree of master inbusiness,---.
Peoples' views of taxation in africa: a review of research on determinants of tax compliance ∗ odd-helge fjeldstad (cmi) collette schulz-herzenberg (iss. Tax compliance and the psychology of justice: mapping the field business & management dissertation topics (2018) ~ writepass the writepass journal. Tax compliance dissertation - allow the top writers to do your essays for you #1 affordable and trustworthy academic writing service if you need to know how to compose a perfect research paper, you are to study this.
A dissertation submitted to the university of zambia in partial fulfillment of the requirements attitude towards tax-compliance and to explore adult education. Household employer payroll tax evasion: an exploration based on irs data and on interviews with employers and domestic workers a dissertation presented.
Advanced topics in taxation colloquium indiana university does enforcement crowd out voluntary tax compliance april 12 daniel shaviro, professor of tax,. The aim of this thesis is to investigate the determinants of business tax evasion for transition significantly both tax morale and tax compliance and, seventh. A 3 page research paper that describes the current system, the progressive tax, and then describes the two most prominent alternative proposals, which are the flat tax or a national sales tax, which is also known as the fairtax. Tax compliance dissertation the tax compliance literature is a good example for the fruitful interdisciplinary dialogue between different social sciences.